These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 40288

  • 1. The relative role of dopamine and norepinephrine receptor blockade in the action of antipsychotic drugs: metoclopramide, thiethylperazine, and molindone as pharmacological tools.
    Robinson SE, Berney S, Mishra R, Sulser F.
    Psychopharmacology (Berl); 1979 Aug 08; 64(2):141-7. PubMed ID: 40288
    [No Abstract] [Full Text] [Related]

  • 2. Preferential effect of noncataleptogenic neuroleptics on mesolimbic dopaminergic function.
    Bartholini G.
    Adv Biochem Psychopharmacol; 1977 Aug 08; 16():607-11. PubMed ID: 18902
    [No Abstract] [Full Text] [Related]

  • 3. Differential effects of typical and atypical neuroleptics on alpha-noradrenergic and dopaminergic post synaptic receptors.
    Le Fur G, Burgevin MC, Malgouris C, Uzan A.
    Neuropharmacology; 1979 Jul 08; 18(7):591-4. PubMed ID: 40153
    [No Abstract] [Full Text] [Related]

  • 4. [Current theories on the role of dopamine in the mechanism of action of neuroleptic drugs].
    Płaźnik A, Kostowski W.
    Psychiatr Pol; 1984 Jul 08; 18(1):39-47. PubMed ID: 6146150
    [No Abstract] [Full Text] [Related]

  • 5. Effects on striatal and mesolimbic dopamine systems of a new potential antipsychotic drug -mezilamine- with weak cataleptogenic properties.
    Uzan A, Le Fur G, Mitrani N, Kabouche M, Donadieu AM.
    Life Sci; 1978 Jul 17; 23(3):261-73. PubMed ID: 29181
    [No Abstract] [Full Text] [Related]

  • 6. A comparison of the effects of anti-psychotic drugs on pituitary, striatal and limbic system post-synaptic dopamine receptors.
    Meltzer HY, Simonovic M, Fang V, Piyakalamala S, Young M.
    Life Sci; 1978 Aug 14; 23(6):605-9. PubMed ID: 29199
    [No Abstract] [Full Text] [Related]

  • 7. Dopamine D-2 receptors inhibit D-1 stimulated cyclic AMP accumulation in striatum but not limbic forebrain.
    Kelly E, Nahorski SR.
    Naunyn Schmiedebergs Arch Pharmacol; 1987 May 14; 335(5):508-12. PubMed ID: 2441268
    [Abstract] [Full Text] [Related]

  • 8. Neuroleptic drugs and the dopamine hypothesis.
    Clow A, Jenner P, Theodorou A, Marsden CD.
    Lancet; 1979 Apr 28; 1(8122):934. PubMed ID: 86713
    [No Abstract] [Full Text] [Related]

  • 9. Drug effects on pre- and postsynaptic dopamine receptors.
    Andén NE, Grabowska-Andén M.
    Adv Biochem Psychopharmacol; 1980 Apr 28; 24():57-64. PubMed ID: 6105802
    [No Abstract] [Full Text] [Related]

  • 10. The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations.
    Rubin RT, Hays SE.
    Psychoneuroendocrinology; 1980 Apr 28; 5(2):121-37. PubMed ID: 6104835
    [No Abstract] [Full Text] [Related]

  • 11. Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics.
    Kendler KS, Bracha HS, Davis KL.
    Eur J Pharmacol; 1982 Apr 23; 79(3-4):217-23. PubMed ID: 6124428
    [Abstract] [Full Text] [Related]

  • 12. Differential affinities of molindone, metoclopramide and domperidone for classes of [3H]spiroperidol binding sites in rat striatum: evidence for pharmacologically distinct classes of receptors.
    Rosenfeld MR, Dvorkin B, Klein PN, Makman MH.
    Brain Res; 1982 Mar 04; 235(1):205-11. PubMed ID: 6145486
    [Abstract] [Full Text] [Related]

  • 13. Changes in catalepsy and receptor sensitivity following chronic neuroleptic treatment.
    Allikmets LH, Zarkovsky AM, Nurk AM.
    Eur J Pharmacol; 1981 Oct 22; 75(2-3):145-7. PubMed ID: 6119215
    [No Abstract] [Full Text] [Related]

  • 14. [Dopamine hypothesis in schizophrenia--recent findings in limbic system abnormality].
    Toru M, Watanabe S, Kaneno S.
    Nihon Rinsho; 1978 Oct 22; 36(1):76-82. PubMed ID: 24768
    [No Abstract] [Full Text] [Related]

  • 15. Regulation of striatal acetylcholine concentration by D2-dopamine receptors.
    Sethy VH.
    Eur J Pharmacol; 1979 Dec 20; 60(4):397-8. PubMed ID: 43263
    [No Abstract] [Full Text] [Related]

  • 16. Differential dose- and time-dependent effects of molindone on dopamine neurons of rat brain: mediation by irreversible inhibition of monoamine oxidase.
    Meller E, Friedman E.
    J Pharmacol Exp Ther; 1982 Mar 20; 220(3):609-15. PubMed ID: 6121048
    [Abstract] [Full Text] [Related]

  • 17. Blockade of the dopamine depressor response by molindone, a newly introduced neuroleptic.
    Nandal NV, Mane VR, Balsara JJ, Chandorkar AG.
    Indian J Physiol Pharmacol; 1980 Mar 20; 24(2):143-7. PubMed ID: 6103868
    [Abstract] [Full Text] [Related]

  • 18. Metoclopramide and sulpiride as selective blocking agents of pre- and postsynaptic dopamine receptors.
    Alander T, Andén NE, Grabowska-Andén M.
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jun 20; 312(2):145-50. PubMed ID: 7402361
    [Abstract] [Full Text] [Related]

  • 19. [Proceedings: Dopamine receptor and antipsychotic effects (author's transl)].
    Karobath M.
    Arzneimittelforschung; 1976 Jun 20; 26(6):1029-30. PubMed ID: 9103
    [No Abstract] [Full Text] [Related]

  • 20. [Effect of dimetpramid and metoclopramide on the rate of catecholamine turnover in the subcortical-stem structures of the rat brain].
    Legeza VI, Kamynina MF, Markovskaia IV, Shagoian MG, Martirosov KS.
    Farmakol Toksikol; 1986 Jun 20; 49(4):25-7. PubMed ID: 3019759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.